摘要
目的观察急性ST段抬高型心肌梗死(ST-elevation myocardial infarction,STEMI)行急诊PCI术患者使用替罗非班的有效性及安全性。方法 80例患者随机分成两组:替罗非班组及对照组各40例。替罗非班组术中给予替罗非班,术后持续使用24h,随访7d。对照组不给予替罗非班,其余相同。观察两组术中TIMI血流分级,ST段回落百分比例,术后7d左室射血分数(LVEF),再灌注心律失常及术后7d内出血事件。结果替罗非班组PCI术后TIMI3级血流的例数明显高于对照组(38例VS30例,P<0.05),替罗非班组ST段回落百分比例与对照组相比差异有统计学意义(15例VS 7例,P<0.05)。替罗非班组和对照组PCI术后7d出血事件差异无统计学意义(P>0.05)。结论替罗非班可以增加急性ST段抬高型心肌梗死患者PCI术中TIMI 3级血流,可增加ST段回落百分比,不增加术后7d内出血事件。
Objective To study the therapeutic effects and safety of tirofiban on acute ST-elevation myocardial infarction （STEMI） patients undergoing PCI. Methods 80 patients with STEMI were randomized to receive tirofiban （n=40） or not （n=40）. TIMI flow, percentage of ECG-ST （sumSTR）, Reperfusion arrhythmia,left ventricular ejection fraction （LVEF） and bleeding status were measured during PCI or 7days post-PCI. Results Baseline characteristics of patients between tirofiban and control groups were similar （P〉0.05）. During PCI,TIMI 3 flow was high in tirofiban group compared to control group （38 VS 30,P〈0.05）. SumSTR was high in tirofiban gro.up compared to control group （15 VS 7,P〈0.05）. However,no significant changes were found in bleeding in both two groups for 7 days post-PCI. Conclusion Tirofiban was shown to be a beneficial on TIMI 3 flow and sumSTR. Tirofiban do not increase the incidence of bleeding in patients with STEMI undergoing PCI.
出处
《中国热带医学》
CAS
2012年第8期981-983,共3页
China Tropical Medicine
